Sign inJoin waitlistJoin the waitlist

Emi Caywood

Director, Transplant & Cellular Therapy · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY

Credentials: · · ·

History

Transplant & Cellular Therapy · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
Present

National Cancer Institute
2008–2009
Pediatric Hematology Oncology
Johns Hopkins University School of Medicine
2005–2008
MedStar Georgetown University Hospital
2002–2005
Robert Wood Johnson Medical School
1998–2002
Cornell University
1994–1998

Research

Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma
Ophthalmology · 2014 · 214 citations
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia
Case report · Blood · 2008 · 194 citations
Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy
Review · Current Opinion in Ophthalmology · 2014 · 136 citations

Michael Pulsipher
13 papers
Sonali Chaudhury
9 papers
Catherine Aftandilian
8 papers
Lolie Yu
8 papers
Christopher Dvorak
7 papers
Donald Kohn
7 papers
Jeffery Bednarski
7 papers
Jennifer Heimall
7 papers · 3 as a fellow
Jennifer Puck
7 papers
Kira Bona
7 papers
LG
Linda Griffith
7 papers
Luigi Notarangelo
7 papers

Grants

Nemours NCI Community Oncology Research Program (NCORP)
National Cancer Institute · UG1
Contact PI · $3.7M · Nemours Children's Hospital, Delaware
2014–2027

Clinical trials

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Site PI · Recruiting
Alliance for Clinical Trials in Oncology
2025–2029
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
Site PI · Recruiting
University of Rochester
2024–2030